Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

Complete Sonida Senior Living Corp. stock information by Barron's. View real-time SNDA stock price and news, along with industry-best analysis.

From criminal courts to immigration hearings, everyone has due process rights. Here’s everything you need to know about this constitutional right.

The sNDA, if approved, would expand the indication for Revuforj to include patients with R/R AML who have an NPM1 mutation, the most common genetic alteration in AML.

The sNDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025. RTOR allows ...

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in ...

Health insurers plan to change pre-approval process By 2027, companies will have sped up decisions and coverage for many ...